A virus that once filled pediatric hospital beds and terrified new parents is finally being pushed back—before babies are ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

A senior scientist at the US CDC has resigned, warning that changes in leadership may weaken the country’s vaccine program.

Kennedy Jr. in the country's top health position, use of a long-approved vaccine against measles, mumps, rubella, and ...

Dr. Fiona Havers, who studied medicine at the University of Washington, says the wholesale dismissal of the CDC's scientific ...

A newly posted agenda for next week’s meeting of the just-appointed group of outside vaccine advisers to the US Centers for ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from ...

A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached 75% (95% CI 50-87), according to researchers led by Diya Surie, MD, of the CDC in Atlanta.

RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

U.S. Health Secretary Robert F. Kennedy Jr.’s new vaccine advisers meet next week, but their agenda suggests they’ll skip ...